Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 3/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30943695 | 0.93 | KMT2A (0.41) | KMT2ATLR2ACE | |
| SCHEMBL31246035 | 0.90 | KMT2A (0.47) | KMT2ATLR2MDM4TP53 | |
| SCHEMBL17196273 | 0.89 | KLK5 (0.46) | KMT2AACEKLK5TDP1MAPT | |
| SCHEMBL29539925 | 0.89 | KLK5 (0.46) | KMT2AACEKLK5TDP1MAPT | |
| SCHEMBL20646383 | 0.89 | KLK5 (0.46) | KMT2AACEKLK5TDP1MAPT | |
| SCHEMBL31478692 | 0.89 | KLK5 (0.46) | KMT2AACEKLK5TDP1MAPT | |
| SCHEMBL30943632 | 0.87 | KMT2A (0.46) | KMT2ATLR2 | |
| SCHEMBL31309891 | 0.85 | KLK5 (0.42) | KMT2ATLR2KLK5TLR1 | |
| SCHEMBL31309835 | 0.84 | KLK5 (0.43) | KMT2ATLR2KLK5TLR1 | |
| SCHEMBL30874603 | 0.84 | PAX8 (0.43) | KMT2ATLR2TDP1PAX8TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4643877-A1 | COMPOSITION OF CD40-BINDING MOLECULE AND PHARMACEUTICAL USE THEREOF | Suzhou Suncadia Biopharmaceuticals Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| US-20250152722-A1 | DRUG CONJUGATE OF GLUCOCORTICOID | SHANGHAI SENHUI MEDICINE CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| EP-4470569-A1 | DRUG CONJUGATE OF GLUCOCORTICOID | Shanghai Shengdi Pharmaceutical Co., Ltd (CN) | 2024-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152722-A1 | DRUG CONJUGATE OF GLUCOCORTICOID | SHBG, CYP17A1, HSD17B7 | KMT2A 2814/4885TLR2 3268/4885ACE 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.